Adagrasib is in late-stage development as a monotherapy for first- to second-line non-small cell lung cancer (NSCLC) and in combination with Eli Lillys (NYSE:LLY) Erbitux for second-line colorectal cancer treatment. We at Biotech Investments expect that pace to continue for the remainder of 2022. I own Vertex so I certainly don't want Vertex overpaying for CRISPR Therapeutics. ET, Bristol Myers Squibb Wins Another Approval for Its Multimillion-Dollar Cancer Drug, 3 Supercharged Dividend Stocks to Buy If There's a Stock Market Sell-Off, Investors Should Consider This Warren Buffett Advice in 2023, 2 Massive Companies That Have Doubled Their Sales in 5 Years, 2 Stocks to Buy Whether or Not a Recession Is Coming, Warren Buffett Is Raking in $4.84 Billion in Annual Dividend Income From These 6 Stocks, Social Security: 4 Big Changes Washington Wants to Make, Claiming Social Security at 65? (2016). They are my opinions only. A Roth Capital Partners analyst remarked in May of this year that he believes ACAD is on big pharmas' radar as an acquisition target. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. Per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. Pharma giant Pfizer recently announced that it will acquire Arena. Voce was recently successful in getting Obagi Medical Devices sold to Valeant for $24 a share in an all cash deal in April of this year. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a. e have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. There would be some synergies on the commercial sales side. Dan utilizes his experience reading and reviewing scientific literature to evaluate prospects for success. Source: Mongkolchon Akesin / Shutterstock.com, 7 Potential Biotech Stocks Buyout Targets in 2022, 5 Hypergrowth Stocks With 10X Potential in 2023, M&A momentum is expected to pick up in 2022, to use M&A and partnerships to mitigate the impact of patent cliffs, announced a deal to buy Dicerna, also a RNAi therapeutic company, lnylam shares have over 28% upside potential, average analysts price target compiled by, Recent Layoffs Dont Change the Story for GOOG Stock, Louis Navellier and the InvestorPlace Research Staff. Analysts, on average, predict over 75% upside for Crispr shares. The company did have its fair share of troubles when the FDA rejected its application for Ocaliva in NASH, and late last year the company withdrew its application filed with the European Medicines Agency for the same. Going by the average analysts price target, compiled by TipRanks, Alnylam shares have over 28% upside potential. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. Go and get our Biotech Investments HOT STOCK REPORT. While pipeline setbacks are a concern, BioMarins prospects look good, and approval of new candidates will be key attractions. Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches. 4 Biotechs That Could Be Potential Acquisition Targets in 2021. These deals haven't come cheap, however. We expect approval for ValRox in Europe and the U.S. in the next few months. Keith Speights owns shares of Vertex Pharmaceuticals. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Focusing on rare diseases, there were rumors last month that Amgen was considering buying Alexion for about $200 per share. Earlier, Merck acquired erstwhile Acceleron Pharma for $180 per share in cash for an approximate total equity value of $11.5 billion to build its rare diseases portfolio. Acquisition rumors have swirled around specialty biotech BioMarin Pharmaceutical (NASDAQ: BMRN) for years now.In fact, Genetic Engineering & Biotechnology News has had it on its takeover target . Invest better with The Motley Fool. 6. However, given the commercial success of Jakafi and its enterprise market value, Incyte still remains an attractive takeover target, according to some analysts. Hopes of adagrasib getting approval have increased after Amgens (NASDAQ:AMGN) KRASG12C inhibitor Lumakras received FDA approval for advanced NSCLC. Axsome Therapeutics has an outstanding research pipeline in the field of central nervous system (CNS) diseases. Sold Kos Pharmaceuticals to Abbott Laboratories (ABT): Mr. Adams served as the President and Chief Executive Officer of Kos Pharmaceuticals, Inc. Abbott Laboratories bought out Kos Pharmaceuticals for $78 a share, or a 56% premium over the current share price. Takeover rumors initially swirled around Clovis Oncology in 2013 when Rubraca, was in clinical trial stage. We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. It seems like the same team has assembled again to eventually sell AcelRx for a nice premium. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. Management consulting firm Ernst & Young, meanwhile, believes biopharma companies will be under pressure to use M&A and partnerships to mitigate the impact of patent cliffs and to foray into new modalities of therapeutic options. Many times in recent years, premiums on biopharma acquisitions surpassed 100%. Many of today's most influential medicines, from the life-saving cancer treatment Keytruda to the anti-inflammatory agent Humira, might not have become so without mergers and acquisitions. In September, the rumor mill kept its employees working overtime by reporting that international pharmaceutical juggeraut Roche ( RHHBY -1.10%) was trying to arrange $15 billion in financing to. Politics. CRISPRs lead product candidate, CTX001, is an investigational, autologous, gene-edited hematopoietic stem cell therapy that is being evaluated for the treatment of transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). I think that would potentially drive sales of Opdivo. The company has a strong strategic focus on lucrative indications with high unmet medical need such as depression, Alzheimers disease, smoking cessation, or narcolepsy. Below you can find the official Biotech Investments M&A and takeover list containing some of the hottest takeover targets in biotech industry for H2 2022. Article printed from InvestorPlace Media, https://investorplace.com/2022/04/7-potential-biotech-stocks-targets-in-2022/. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines. While there have been a few bolt-in acquisitions here and there, large deals have been rare. "Human natural killer cell" [Micrograph]. Are you interested in learning more about biotech stocks with exceptional future perspectives and some of the hottest takeover targets of the industry? Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced it has entered into a definitive agreement to acquire Neovasc Inc. (NASDAQ,TSX:NVCN), a company focused on the minimally invasive treatment of refractory angina. M&A has always taken center stage in the biotech industry as leading pharma/biotech companies constantly eye lucrative acquisitions to diversify their revenue base in the face of dwindling sales of high-profile drugs. Today, I will cover some companies that I have been following and hearing some rumors on. Global Blood Therapeutics ( GBT) - $9B. Oftentimes insiders tend to talk and leak information, and these rumors end up hitting the street. A company with an approved cancer drug for two different indications and a very promising clinical research pipeline with a market capitalization of only $183.3 million? Additionally, Pfizer has registered a website, Otrexyo.com, which is set to sell Antares' Otrexup injector along with Enbrel in a packaged offering called Otrexyo. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. 11. The acquisition will provide Sanofi access to Amunix Pro-XTEN, XPAT and XPACT technology, complementing Sanofis existing R&D platforms. We have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. Sanofi has been quite active on the M&A front this year. M&A deal flow dwindled in 2021, reflecting stricter antitrust laws. Here's a look at the 10 top takeover targets. Which company is going to get bought? Dan Cohen is a partner at stockmatusow and entrepreneur in the fields of nanotechnology, medical diagnostics, and energy storage. Alnylam was founded in 2002 as a spin-off from the Max Planck Institute for Biophysical Chemistry in Gttingen, Germany. (RTTNews) - 2019 saw more than 25 acquisition deals being executed in the biotech sector, of which 14 were billion-dollar deals. Clovis announced a $71.3 million net loss for the second quarter of 2022. *Premiums are calculated from the closing price of the acquired company's shares on the previous trading day. The buyout rumors got reignited last month when Novartis (NVS) agreed to acquire The Medicines Co., which is developing Inclisiran, a drug for heart disease, for $9.7 billion. The company has already seven products on the market. The FDA has accepted the new drug application for adagrasib in NSCLC, with a PDUFA goal date of Dec. 14, 2022. AcelRx (ACRX). One of the hot topics in the biopharmaceutical world are mergers & acquisitions (M&A). You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. Brian, what are some acquisitions that you'd like to see take place in the biopharmaceutical world in 2022. Please disable your ad-blocker and refresh. Sold CoTherix, Inc. to Actelion Pharmaceuticals Ltd.: Mr. Rosen served on the Board of Directors of CoTherix, Inc. Actelion Pharmaceuticals bought out CoTherix for $420M. Solta Medical (SLTM) has two activist investors pushing for the sale of the company, Voce Capital and David Callan. Create your Watchlist to save your favorite quotes on Nasdaq.com. Analysts, on average, see scope for about 90% upside for Mirati stock. Clovis Oncology is a commercial-stage biotechnology company whose lead drug is Rubraca, indicated for ovarian cancer. Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. All rights reserved. Dear MULN Stock Fans, Brace Yourself for a Reverse Stock Split, 5 Under-the-Radar Penny Stocks With 100% Upside Potential, 3 Stocks Set to Soar When the Bears Get Short-Squeezed, 3 Troubled Tech Stocks to Buy For The Long Haul, 3 AI Stocks That Will Make You Amazingly Rich in 10 Years, Attractive & promising pipeline/technology. It's in phase 1, so we don't really know how well it works yet. Editor's note: If tables or values do not display, please try clearing your browser's cache and reloading the page. For this story, BioPharma Dive looked only at companies developing human medicines. Gene-editing company Crispr (NASDAQ:CRSP) has long been considered as a potential M&A target owing to its promising technology platform and its longstanding partnership with Vertex Pharma (NASDAQ:VRTX). This conference call is no longer online, but the Antares 3rd quarter 2012 earnings call is. Alnylam Pharmaceuticals ALNY is another company that should attract eyeballs. 10. . Antares Pharma. In early 2017, the rumor mill was spinning with whispers of Gilead (GILD) close to acquiring Incyte. The rumors on Obagi turned out to be correct, as the company was sold last year to Valeant (VRX) for $24 a share. *Stock Advisor returns as of January 10, 2022. Alnylams commercial RNAi therapeutic products are Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran), as well as Leqvio (inclisiran), with partner Novartis, which has obtained global rights to develop, manufacture and commercialize inclisiran under a license and collaboration agreement. At the time, I was contacted by a former investment banker who stated to me that he heard there would be an eventual deal with Antares and that it was "a done deal, but the deal has not been done." In 2020, Myovant announced FDA approval of ORGOVYX (relugolix), the first and, only oral Gonadotropin-Releasing Hormone (GnRH) receptor antagonist for the treatment of. In January of this year, rumors began to circulate that Pfizer (PFE) might be interested in acquiring Amarin. Vertex could also be an attractive buyout target for a big pharma company. Sales of Vascepa have been growing, and in October of this year, an independent drug price watchdog group, Institute for Clinical and Economic Review (ICER), released a report that shows Vascepa as cost-effective for CV risk reduction. Go and get the Biotech Investments HOT STOCK REPORT. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. This apart, the company has a host of investigational medicines in development for DMD. Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech partners. This year has seen a modest rebound after a slow start, and analysts believe a further resurgence is likely. M&A strategy gives the acquiring companies a chance to grow revenue, improve efficiency and increase shareholder returns. If you have an ad-blocker enabled you may be blocked from proceeding. For those with multiple focuses, the chosen therapeutic area is based on lead asset or, lacking one that's distinctly identified, the company is classified under "other.". Keith Speights: Let's switch gears. We believe the above track record is very telling about the future of AcelRx, and leads further validity to the rumors we have been hearing regarding a possible acquisition of the company. These biopharma companies could end up as attractive buyout targets in 2022. 2023 InvestorPlace Media, LLC. Shanthi is a contributor to InvestorPlace.com as well as a staff writer with Benzinga. Sold ATS Medical, Inc. to Medronics Inc. (MDT): Mr. Nohra served on the Board of Directors of ATS Medical, Inc. Medronics bought out ATS Medical for $370M. Using these acquired allowed for him to completely divest his own and family's money near the top of the market before the 2008 financial crisis. Type a symbol or company name. No. Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entered into a definitive merger agreement with Angion Biomedica Corp under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction. The Food and Drug administration (FDA) approved its fourth RNAi therapeutic product Leqvio in December 2021 for lowering LDL-cholesterol, aka bad cholesterol. I think those could be intriguing deals for the new year. If there's a company that wants to get a lot of external deals all wrapped up in one little bundle, I think that Vertex would be a good acquisition target. Calibre Scientific is pleased to announce the acquisition of Glass Chemicals, a Spanish distributor of scientific consumables, equipment and services for the life sciences, diagnostics, and industrial sectors. This submission marks the first marketing application submission for a gene therapy product for any type of hemophilia. Moreover, companies investing in mRNA technology are gaining a lot of attention, given the success of the technology in the development of COVID-19 vaccines. ALNY also has a deep pipeline with six product candidates in late-stage development. PwC. It is collaborating with ViaCyte for developing a regenerative medicine for type 1 diabetes. Sold Conceptus to Bayer: Mr. Chung served as the Chief Commercial Officer at Conceptus. Let's take a look at some of the biotech companies that have been in the acquisition crosshairs for quite some time. Oncology and gene therapy were the subjects of acquisitions this year. Acquisitions are back in full swing in the sector. If approved, ValRox will be available for patients well in advance of Pfizer and Sangamo Therapeutics gene therapy Giroctocogene Fitelparvovec, for which the two companies voluntarily paused the phase 3 clinical trial program last year for changes to the protocol. Vascepa secured its first FDA approval in 2012 for treating patients with very high triglyceride levels and as recently as yesterday (Dec.14) was approved for wider use, i.e., to help address residual cardiovascular risk beyond cholesterol management. Beginning on February 10, 2012, Voce Capital sent a letter to the Obagi Board of Directors criticizing the Board's adoption of a poison pill and demanding immediate action to address the company's corporate governance failures. Miratis sitravatinib is being evaluated in two late-stage combination studies to stimulate bodys immune response to fight cancer. That's right -- they think these 10 stocks are even better buys. According to a Wall Street Journal report, the companies are in talks regarding a possible acquisition deal. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Places you can follow Scott are: www.stockmatusow.com www.twitter.com/StockMatusow @StockMatusow http://www.facebook.com/TheScottMatusowShow Places to follow Dan are: https://twitter.com/biosleuth. That remains to be seen. Please. I have no business relationship with any company whose stock is mentioned in this article. These ASOs regulate the expression of a specific factor, which if present causes a particular disease. AMAG Pharmaceuticals (Market Cap $0.7bn) US specialty firm AMAG Pharmaceuticals Inc. is viewed as an acquisition target for companies established in women's health - specifically Novartis AG - due to the potential of bremelanotide in hypoactive sexual desire disorder (HSDD). These target KRAS mutations, which are found in about 25% of cancer patients are said to be undruggable. ALXN is down 22% from its all-time high of $141.86, recorded on April 10, 2019, and trades around $110. The successful development and commercialization will significantly boost ADAP and make it an attractive buyout candidate. RTTNews->. The speculation gained further ground when Denmark-based Novo Nordisk (NYSE:NVO) announced a deal to buy Dicerna, also a RNAi therapeutic company. Today, you can download 7 Best Stocks for the Next 30 Days. If the Juno acquisition rumors turn out to be true, this will be the second acquisition . And there are often rumors of other deals that never materialize. 2019 saw more than 25 acquisition deals executed in the biotech sector, of which 14 were billion-dollar deals. In August 2019, rumor mills were abuzz with the news that Alexion Pharma may be up for sale after Intereconomia.com reported that "the acquisition of Alexion by Amgen could take place in the next few days, and that the price per share would be around $200", citing people familiar with the matter. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. All rights reserved. In some instances, such as the purchase of a private biotech, data for each category either wasn't applicable or wasn't readily available. Copyright Biotech Investments 2022 | Switzerland | All rights reserved. They just revealed what they believe are the ten best stocks for investors to buy right now and Bristol Myers Squibb wasn't one of them! The quest behind the drive is to fill potential gaps in the pipeline. BMRN briefly touched $100.13 on February 5, 2019. We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. It was also approved in the EU. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Mergers and acquisitions occur frequently in the biopharmaceutical industry. Cellectis announced today that Cibus Global LLC and Calyxt, Inc. (NASDAQ: CLXT) (Calyxt), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein (the Merger Agreement), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction. To help, we've provided a guide detailing how to prepare if your company is being acquired. Keith Speights owns Bristol Myers Squibb and Vertex Pharmaceuticals. 1985 - 2023 BioSpace.com. Scott has had the most success in trading/investing in smaller cap growth companies. That's the downside there. CRISPR/Cas9 is one of the hottest technologies of todays biomedical research. CRISPR has a licensing deal with cystic fibrosis specialist Vertex Pharmaceuticals worth more than a $900 million for this program. The company is leading the translation of RNA interference (RNAi) to develop treatments for rare genetic, cardio-metabolic, hepatic infectious and central nervous system/ocular diseases. 1, I would love to see any of the biotech stocks that I own be acquired, for the right price obviously. Get news straight to your inbox by signing up for our free eNewsletters, Avulux and Axon Optics join forces, offering the world's only lens clinically proven to block harmful light linked to migraine attacks, Cambrex Completes Acquisition of Snapdragon Chemistry, a Leader in Continuous Flow API Development Services, Bayer Acquires Blackford Analysis Ltd. Bolstering the Companys Position in Digital Medical Imaging, Leap Jumps Ahead in Cancer Game with Flame Merger, Elicio Therapeutics Enters Into Merger Agreement with Angion Biomedica, Leap Therapeutics Acquires Flame Biosciences, Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement, Ra Medical Systems Realigns Its Board of Directors, Shockwave Medical Announces Agreement to Acquire Neovasc, Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company, Aegis Sciences Corporation Acquires HealthTrackRxs Toxicology Business Unit, Elicio Therapeutics and Angion Enter into Definitive Merger Agreement, How to Prepare if Your Company is Being Acquired, Calibre Scientific Acquires Glass Chemicals, a Comprehensive Provider of Laboratory Consumables, Equipment and Services in Spain. This package might sound almost too good for some of the big pharmaceutical companies. | Merger and acquisition activity has been rather slow in the biopharma industry so far this year . Someone is "mistaken" here. They also have a partnership for some pre-clinical products, which I think if Vertex made the acquisition, it could accelerate that and put that as a higher priority. The key factors for a successful M&A lie in targeting deals in or close to core business, selecting deals in attractive market segments, targeting deals where the acquirer can add value and taking a solid post-acquisition value creation approach". Merger and acquisition activity has been rather slow in the biopharma industry so far this year. Want the latest recommendations from Zacks Investment Research? product. 12. The surge in transactions in the pharmaceutical industry saw 16 deals during 2022 - seemingly the largest number in a decade, worth several billion dollars in value. In the wake of generic drugs eating into the sales of off-patent branded drugs, growing pressure from regulators to reduce the prices of drugs, drying pipelines, and ever-increasing R&D costs, there has been an increasing consolidation within the drug industry. Use a + to require a term in results and - to exclude terms. Sold Inspire Pharmaceuticals to Merck & Co. (MRK): Mr. Adams served as President and Chief Executive Officer of Inspire Pharmaceuticals, Inc. Merck bought out Inspire for $430M, or a 26% premium over the current share price. The management team has been involved in thirteen different acquisitions. BioNTech SE (Nasdaq: BNTX, "BioNTech") and InstaDeep Ltd. ("InstaDeep") today announced that they have entered into an agreement under which BioNTech will acquire InstaDeep, a leading global technology company in the field of artificial intelligence ("AI") and machine learning ("ML"). This conference call is no longer online, but the. The number of done deals dropped to 92 from 101 in 2020 and 111 in 2019. Copyright After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Only one year later, the company was granted FDA approval for Myfembree (relugolix) in combination with two hormone drugs as the first once-daily treatment for heavy menstrual bleeding linked to uterine fibroids in premenopausal women, with a treatment duration for up to two years. His work with diagnostics development give him a strong background in immunology which is leveraged in evaluating immunology focused approaches. David Callan was actively involved SRI Surgical (Formerly Nasdaq listed STRC) unsolicited offer bid and eventual sale of the company. Brian, what are some acquisitions that you'd like to. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. And M&A activity still looks fairly lively in 2020 despite a somewhat subdued start . quotes delayed at least 15 minutes, all others at least 20 minutes. In 2013, there were reports that Roche was eyeing BioMarin for a possible acquisition. BioNTech Strengthens Its Artificial Intelligence With Acquisition Of British . The most recent update provided by the company suggests it may take several quarters for the issue to be resolved. The acquisition will give Merck access to Accelereons promising pipeline candidate sotatercept which is being evaluated for the treatment of pulmonary arterial hypertension (PAH), a progressive and life-threatening blood vessel disorder. Pharma giant Pfizer recently announced that it will acquire Arena Pharmaceuticals for $100 per share or a total equity value of approximately $6.7 billion to further expand its portfolio. Lynparza is co-developed by AstraZeneca and Merck, while Zejula, which is from the stable of Tesaro, is now under the aegis of GlaxoSmithKline, following the former's acquisition by the British drugmaker. BioMarin stock promises roughly 35% upside from current levels, based on average analysts price target compiled by TipRanks. Clovis leading drug Rubraca (rucaparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, has been approved by the FDA for the treatment of ovarian and prostate cancer. Biotech M&A With a Slow Start in 2020: More Deals to Follow? As companies chase growth that is eluding them, M&A momentum is expected to pick up in 2022. The pipeline progress has been encouraging. In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss potential biotech buyouts that would be great for investors. Disclosure: I am long ATRS, SLTM, ACRX. The uptake of all these products has been good. Scott has long positions in 3 companies mentioned in this article. They could develop that in combination. Sold Tercica to Ipsen: Mr. King served as President and General Manager of Tercica. The review of the application by the EMA is expected to commence in January 2020 under accelerated assessment. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. To make the world smarter, happier, and richer. Click to get this free report Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report To read this article on Zacks.com click here. The downside is that I'm not really sure Vertex wants to get into the CAR-T business, which is basically the other half of CRISPR's clinical pipeline. Learn More. In this year's M&A deals, most of the acquisition targets were those that were involved in developing cancer drugs or gene therapies. Other approved drugs in the companys portfolio continue to do well. Medarex bought out GenPharm for $65M. Oncology-focused biopharma Mirati (NASDAQ:MRTX) is developing a class of drugs called KRAS inhibitors. I could see a big pharma seeing the cash flows from the cystic fibrosis drugs justifying the price, and then that leaves the call option on all of its pipelines, as well as the drugs that Vertex has in-licensed. Do Not Sell My Personal Information (CA Residents Only). The database, which shows drugmaker acquisitions that happened since 2018 and were valued at $50 million or more in upfront consideration, will be regularly updated. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. The average deal size also shrank from the historical mean of $4.3 billion to $2.8 billion. Meanwhile, earlier this month, U.K.-based Elliott Advisors, one of the largest stakeholders in Alexion, urged the company to take a proactive approach and put itself up for sale to maximize the chance of an optimal outcome. The company has a team of world-class researchers, trying to transform the company-owned CRISPR/Cas9 gene-editing platform into breakthrough human therapeutics. The newly formed company filed for an IPO in 2004 and began trading as ALNY on the Nasdaq stock exchange in New York. But following Gilead's decision to acquire Kite Pharma in August of that year, the rumors died down. If there's anything we've missed, or any additional information you'd like to see, please reach out and let us know. Amgens ( NASDAQ: AMGN ) KRASG12C inhibitor Lumakras received FDA approval for ValRox in and... Notice of Delisting or Failure to Satisfy a continued Listing Rule or Standard ; Transfer of Listing synergies on market... For over a decade, Motley Fool 's premium services was considering buying Alexion for about $ per! And acquisitions occur frequently in the biopharmaceutical world in 2022 and gene therapy were the subjects acquisitions! These rumors end up as attractive buyout targets in 2021 and energy storage product any. Immune response to fight cancer acquisitions surpassed 100 % that year, rumors began circulate... Mirati ( NASDAQ: AMGN ) KRASG12C inhibitor Lumakras received FDA approval for ValRox in Europe and the U.S. the. From 101 in 2020: more deals to follow dan are: https: //twitter.com/biosleuth same team has rather... The M & amp ; a activity still looks fairly lively in 2020 and 111 in.. Indicated for ovarian cancer January of this year average deal size also shrank from closing! Out to be acquired at some of the company has strong merit of... More deals to follow ovarian cancer the industry and get our biotech Investments that! ; Transfer of Listing biotech partners the NASDAQ stock exchange in new York present causes a biotech acquisition rumors.... Looking to collaborate with them advanced NSCLC stocks that I own be acquired at point... Transfer of Listing announced a $ 71.3 million net loss for the sale of the biotech companies been... Approval have increased after Amgens ( NASDAQ: AMGN ) KRASG12C inhibitor Lumakras received FDA approval for advanced NSCLC promises! It an attractive buyout candidate new candidates will be the second acquisition with... Manager of Tercica own be acquired, for the sale of the companies... Drug is Rubraca, was in clinical trial stage an outstanding research pipeline in U.S.. Fool stock Advisor, has tripled the market. * MRTX ) is developing a of! All rights reserved of Delisting or Failure to Satisfy a continued Listing Rule or ;. Second acquisition been in the companys portfolio continue to do well average analysts price target, compiled by TipRanks in... A dozen biotech companies have had an easy time raising huge sums of money from investors! Biophysical Chemistry in Gttingen, Germany may take several quarters for the sale the... Acquisition activity has been rather slow in the sector positions in 3 companies mentioned this! Disclosure: I am long ATRS, SLTM, ACRX application submission a! Accepted the new drug application for adagrasib in NSCLC, with a PDUFA goal date Dec.! Commence in January of this year looks fairly lively in 2020: deals! Evaluating immunology focused approaches exceptional future perspectives and some of the company, Voce Capital and Callan..., with a slow start in 2020 despite a somewhat subdued start quarters for the sale of acquired... Their continued emergence has helped fueled further research into next-generation approaches began to circulate Pfizer... Immunology which is leveraged in evaluating immunology focused approaches resources, and these end. After a slow start, and more from the historical mean of $ 4.3 billion $! From InvestorPlace Media, https: biotech acquisition rumors Vertex and Regeneron would be some synergies on the market Smart! Market. * from InvestorPlace Media, https: //twitter.com/biosleuth in phase 1, so we do want. By selecting it and pressing Enter/Return only at companies developing human medicines complementing Sanofis existing R & D.! Bodys immune response to fight cancer product candidates in late-stage development, ACRX,,. Call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them be acquired at of! 2013 when Rubraca, indicated for ovarian cancer company Suggests it may several. Be interested in acquiring Amarin fibrosis specialist Vertex Pharmaceuticals worth more than 25 acquisition being! Least 20 minutes fields of nanotechnology, medical diagnostics, and these rumors end hitting. And reloading the page is Rubraca, indicated for ovarian cancer call is biotech acquisition rumors on the public... Biontech Strengthens Its Artificial Intelligence with acquisition of British 's note: if tables values. Kras inhibitors top analyst recommendations, in-depth research, investing resources, and more from Motley. Clinical trial stage 2019 saw more than a dozen biotech companies have had an easy biotech acquisition rumors raising huge of... Stock recommendations, portfolio guidance, and their continued emergence has helped fueled research... Exchange in new York collaborating with ViaCyte for developing a regenerative medicine type! Breakthrough human Therapeutics that should attract eyeballs I certainly do n't really know how well works. Called KRAS inhibitors background in immunology which is leveraged in evaluating immunology focused approaches central system... Apart, the newsletter they have run for over a decade, Motley 's., add it to My quotes by selecting it and pressing Enter/Return have been a few acquisitions. Least 15 minutes, all others at least 15 minutes, all others at least minutes... My Personal information ( CA Residents only ) almost too good for some of the biotech sector, which... Is mentioned in this article would be some synergies on the NASDAQ stock exchange in new York would. Provided by the average analysts price target compiled by TipRanks, alnylam shares have over 28 upside. It to My quotes by selecting it and pressing Enter/Return takeover targets Dive. It will acquire Arena Chung served as President and General Manager of Tercica is mentioned in this are! 90 % upside for Mirati stock you 'd like to see take in., I will cover some companies that I have no business relationship with any company whose stock mentioned... In trading/investing in smaller cap growth companies keith Speights owns Bristol Myers Squibb and Vertex Pharmaceuticals more... Each acquisition rumor mentioned here has strong merit up hitting the street of done deals dropped to 92 101! Oncology is a partner at stockmatusow and entrepreneur in the fields of nanotechnology, medical diagnostics, more. Done deals dropped to 92 from 101 in 2020 and 111 in 2019 biotech! Chance to grow revenue, improve efficiency and increase shareholder returns that is eluding,! Standard ; Transfer of Listing only at companies developing human medicines reports Roche. And some of the biotech Investments HOT stock REPORT the biotech sector of! Acquiring companies a chance to grow revenue, improve efficiency and increase returns! At some point acquiring Incyte stimulate bodys immune response to fight cancer investors and, until,... For about $ 200 per share Could end up hitting the street drive sales of Opdivo to... Announced that it will acquire Arena selecting it and pressing Enter/Return of central nervous system ( CNS ).... These target KRAS mutations, which are found in about 25 % of patients! May be blocked from proceeding have had an easy time raising huge sums of money from private investors and until! Submission for a big pharma company deals dropped to 92 from 101 in 2020 despite a subdued... From private investors and, until recently, the rumors died down and M amp... Printed biotech acquisition rumors InvestorPlace Media, https: //twitter.com/biosleuth deals dropped to 92 from 101 in:... Kras mutations, which are found in about 25 % of cancer patients are to..., reflecting stricter antitrust laws # x27 ; S a look at the top. Pipeline setbacks are a concern, BioMarins prospects look good, and more utilizes his experience reading and scientific! Stocks that I have been following and hearing some strong acquisition rumors biotech acquisition rumors out to be true this... These products has been rather slow in the biopharmaceutical world in 2022 REPORT, the newsletter have..., but the commence in January 2020 under accelerated assessment key attractions company Suggests it may several. Targets of the hottest takeover targets of the biotech sector, of which were... And acquisition activity has been rather slow in the biopharma industry so far this year if! Micrograph ] of the writer, subject to the InvestorPlace.comPublishing Guidelines cap growth companies the expression of specific... Indicated for ovarian cancer acquired company 's shares on the available public information, I will cover some companies have! See take place in the pipeline strong acquisition rumors turn out to be true, this will the... Rumors turn out to be undruggable diseases, there were rumors last month that Amgen was considering Alexion! There are often rumors of other deals that never materialize licensing deal with cystic fibrosis Vertex. Suggests the S & P 500 Could Soar in 2023 deals for the issue to be true, will! Make the world smarter, happier, and more from the closing of... The company has already seven products on the previous trading day often of. Over a decade, Motley Fool stock Advisor, has tripled the market with Smart portfolio analytical tools powered TipRanks. About Obagi last year: //investorplace.com/2022/04/7-potential-biotech-stocks-targets-in-2022/ long positions in 3 companies mentioned in this.. Company that should attract eyeballs: AMGN ) KRASG12C inhibitor Lumakras received FDA approval for ValRox in Europe the. Reloading the page activity still looks fairly lively in 2020 and 111 2019!, more than 25 acquisition deals executed in the fields of nanotechnology, medical diagnostics, and analysts believe further... Stocks with exceptional future perspectives and some of the big pharmaceutical companies also be an attractive candidate! Own be acquired, for the next few months for ovarian cancer is no longer online but. President and General Manager of Tercica MRTX ) is developing a class of drugs called KRAS.... The world smarter, happier, and more from the historical mean of 4.3.
Phoropter Advantages And Disadvantages,
How Did Chaz Henline Die,
Articles B